A new class of drugs, Lu-PSMA-617, track down i prostate cancers resistant achieving good success and extending the life of patients.
This was declared by an international team of researchers including Professor Johann de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research, London, and Medical Oncologist Advisor at the Royal Marsden NHS Foundation Trust, and Professor Ken Herrmann, Director of the Nuclear Medicine Clinic at the University Hospital from Essen, Germany.
Read Also
- Covid Italy, “90% of patients in resuscitation not vaccinated” Aug 10, 2021
- Neither lifestyle changes nor type 2 diabetes drugs reduce cardiovascular disease May 23, 2022
- Brentford achieves promotion to Premier League after 74 years May 30, 2021
- Seven good reasons to drink milk Jun 2, 2020
- 200,000 Cansino vaccines have arrived against the coronavirus: they will be applied to homeless people and refugees Sep 7, 2021
- “Primary Care is nothing more than a rickety structure that is crumbling, incapable of inspiring young doctors” Jun 2, 2021
- Five foods that are good for hypertension Jul 10, 2020